Correction: Study protocol for the POPART study—Prophylactic Oropharyngeal surfactant for Preterm infants: A Randomised Trial


The authors want to alert readers to the following update in the published version. The funding statement of this article is updated with the below statement:

Chiesi Farmaceutici, manufacturers of poractant alfa (Curosurf), supply the study drug free of charge; they had no role in study design; have no role in study conduct; and will have no role in data collection, analysis or interpretation. Further, they will have no role in the decision to present, publish or otherwise report results.

Madeleine Murphy is the recipient of a Clinical Research Fellowship by the National Children’s Research Centre, Dublin (R17637).

Paediatric Clinical Research Infrastructure Network (PedCRIN), a Project of the European Union Horizon 2020 programme designed to support the extension of clinical drug trials in children throughout Europe, also support the study.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.